
    
      To determine the efficacy of Rituximab as first line of treatment of chronic GVHD. Efficacy
      will be defined as he ability to taper prednisone to a dose of 0.25 mg/kg per day by 6 months
      without clinical or GVHD relapse/ recurrence.
    
  